AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Lanosterol synthase

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P48449

UPID:

LSS_HUMAN

Alternative names:

2,3-epoxysqualene--lanosterol cyclase; Oxidosqualene--lanosterol cyclase

Alternative UPACC:

P48449; B4DJZ9; D3DSN0; E9PEI9; G5E9Q9; Q8IYL6; Q9UEZ1

Background:

Lanosterol synthase, also known as 2,3-epoxysqualene--lanosterol cyclase, plays a pivotal role in the cholesterol biosynthesis pathway by catalyzing the conversion of (S)-2,3 oxidosqualene to lanosterol. This enzyme is crucial for the formation of the sterol nucleus, laying the foundation for the synthesis of all steroids.

Therapeutic significance:

The enzyme's involvement in conditions such as Cataract 44, Hypotrichosis 14, and Alopecia-intellectual disability syndrome 4 highlights its potential as a therapeutic target. Understanding the role of Lanosterol synthase could open doors to potential therapeutic strategies for these diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.